Search

Longtime donors Fiona and Stanley Druckenmiller have contributed a transformative gift of $100 million to MSK through their foundation. The gift will be used to launch the Fiona and Stanley Druckenmiller Presidential Innovation Fund.

Deb Schrag, MD, MPH, gastrointestinal oncologist and Chair of the Department of Medicine, presented results from a randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total surgical excision for the treatment of patients with locally advanced rectal cancer.

Memorial Sloan Kettering Cancer Center (MSK) today announced that Kenneth Offit, MD, MPH, and Ross L. Levine, MD, have been elected as Fellows of the AACR Academy, one of the highest honors bestowed by the American Association for Cancer Research (AACR).

A team of investigators from Memorial Sloan Kettering has shown for the first time that tumor growth, metastasis, and chemotherapy resistance are connected to the same molecular changes inside breast cancer cells.

Lisa M. DeAngelis, MD and Elizabeth Schille, RN, OCN were recognized for their work in the the field of neuro-oncology.

The President and CEO and Chair of the Board at Memorial Sloan Kettering Cancer Center introduce the year's highlights in their introductory letter to the 2023 Annual Report.

The Organ Preservation in Patients with Rectal Adenocarcinoma (OPRA) trial demonstrated that the watch-and-wait strategy is safe for patients with stage 2 and stage 3 rectal cancers that achieve a clinical complete response (CCR) or near-complete clinical response (NCR) to total neoadjuvant therapy (TNT).

MSK researchers have identified a compound that kills glioblastoma cells using a mechanism that’s completely different from earlier treatments.